ClinicaliQ Trial Snapshot
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors — Recruiting • Phase I • Oncology • NCT07407933.
- What is being tested: YL201 (an investigational cancer therapy) combined with atezolizumab (an immune checkpoint inhibitor) in a phase Ib/II dose escalation and expansion study across multiple centers.
- Patient eligibility overview: Patients with advanced solid tumors, with Part 1 specifically focusing on previously untreated extensive-stage small cell lung cancer (ES-SCLC) for safety and tolerability assessment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either…
Eligibility Snapshot
- : 1.18 years of age or older. 2. Histologically or cytologically confirmed diagnosis of ES-SCLC 3. Eastern Cooperative Oncology Group performance status of 0 or 1 4. Adequate hematologic and end-organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.